Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

432.76USD
23 Oct 2017
Change (% chg)

$-0.22 (-0.05%)
Prev Close
$432.98
Open
$435.00
Day's High
$437.90
Day's Low
$430.05
Volume
779,256
Avg. Vol
825,115
52-wk High
$543.55
52-wk Low
$325.35

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $46,394.77
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

Regeneron-Sanofi drug succeeds mid-stage study

Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

Oct 16 2017

CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

Oct 16 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

Regeneron-Sanofi throat infection drug succeeds key study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study.

Oct 16 2017

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

Oct 16 2017

BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab

* REGENERON AND SANOFI ANNOUNCE POSITIVE PHASE 2 STUDY RESULTS FOR DUPILUMAB IN PATIENTS WITH ACTIVE MODERATE-TO-SEVERE EOSINOPHILIC ESOPHAGITIS

Oct 16 2017

U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug

A U.S. appeals court on Thursday threw out a ban on the sale of Regeneron Pharmaceuticals Inc and Sanofi SA's cholesterol-lowering drug Praluent, and ordered a new trial after finding a jury was given improper instructions.

Oct 05 2017

UPDATE 3-U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug

Oct 5 A U.S. appeals court on Thursday threw out a ban on the sale of Regeneron Pharmaceuticals Inc and Sanofi SA's cholesterol-lowering drug Praluent, and ordered a new trial after finding a jury was given improper instructions.

Oct 05 2017

BRIEF-U.S. Appellate Court rules Sanofi, Regeneron can continue manufacturing PRALUENT in U.S.

* Appellate Court orders a new trial and vacates permanent injunction in ongoing patent case regarding Praluent® (alirocumab)

Oct 05 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF85.15 --
Pfizer Inc. (PFE.N) $36.40 -0.02
Bayer AG (BAYGn.DE) €117.25 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €84.39 --
Merck & Co., Inc. (MRK.N) $63.40 -0.48
Amgen, Inc. (AMGN.OQ) $180.53 -2.43
Roche Holding Ltd. (ROG.S) CHF234.90 --
Roche Holding Ltd. (RO.S) CHF238.10 --
Eli Lilly and Co (LLY.N) $87.18 -0.05

Earnings vs. Estimates